O7 Therapy is revolutionizing access to mental health services through a digital platform and mobile app offering online therapy, psycho-educational resources, and corporate wellness programs, to empower Arabic-speaking people to pursue their mental wellness journey. We use cutting edge AI in a very engaging user experience producing an effective therapeutic journey. Additionally, we provide Employee Wellness Programs for organizations through a unique B2B2E model, prioritizing the impact of mental health challenges in the workplace, and focusing on raising awareness and understanding, reducing stigma and shame, creating safe and supportive spaces, and implementing strategies that promote mental wellbeing.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, specializes in developing a healthcare platform and application aimed at Alzheimer’s patients. The company's flagship product, the Altoida iPad-based application, is the first validated solution on the market designed to predict the risk of Alzheimer’s Disease before symptoms appear, functioning as a computational biomarker. The application employs the Neuro Motor Index (NMI), which measures subtle micro-errors and micro-movements during everyday tasks, allowing for early detection of cognitive decline up to six years prior to the onset of typical neurodegenerative symptoms. The NMI test is intended for use by healthcare professionals as an adjunctive tool and is not a stand-alone diagnostic method. Altoida's medical device is classified as an FDA Class II medical device and CE marked as Class I, enabling early screening for Mild Cognitive Impairment (MCI) and monitoring cognitive function. After a brief testing period, healthcare providers receive real-time access to comprehensive patient reports via a secure, HIPAA-compliant web dashboard, making cognitive health assessments more affordable and accessible.
Altibbi Ltd. operates a digital health platform for doctors and users in the Middle East. Its platform provides information on various topics, including hypertension, eyes illnesses, allergy allergic, herbalists, and malignant tumors, as well as heart, dental, skin diseases. The company’s solution also includes medical dictionary, articles, guide, and news; and videos, encyclopedia of medicines, and questions and answers. In addition, the company provides services through its mobile applications. Altibbi Ltd. was founded in 2008 and is based in Dubai, United Arab Emirates.
Activ Surgical is a digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes, and accessibility. Its scalable and patent-protected surgical software platform technology is driven by computer vision, artificial intelligence, analytics, and machine learning to enhance a surgeon’s intra-operative decision making, and reduce unintended and preventable surgical complications. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
NuvoAir AB develops Air Next home spirometer, a medical device to monitor lung function. It offers its products online. The company was founded in 2015 and is based in Stockholm, Sweden.
BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors designed to analyze body fluids for health monitoring. Founded in 2012 and originally known as Electrozyme LLC, Biolinq aims to enhance the experience of individuals with diabetes by providing a more affordable and pain-free alternative to conventional continuous glucose monitoring (CGM) systems. The company's platform features minimally invasive electrochemical biosensors capable of measuring multiple analytes, including glucose, ketones, and lactate. This innovative technology not only facilitates easier blood glucose monitoring but also delivers actionable insights into metabolic health, significantly improving the quality of life for patients managing diabetes.
Click Therapeutics, Inc. specializes in the engineering, validation, development, and commercialization of digital therapeutic solutions aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company offers innovative digital therapeutics for a range of conditions, including smoking cessation, major depressive disorder, schizophrenia, insomnia, and chronic pain. Its Digital Therapeutics™ are designed to function independently or alongside traditional biomedical treatments, utilizing the Clickometrics® adaptive data science platform to personalize user experiences and enhance engagement. Notably, Click's smoking cessation program has gained widespread access through various payers and providers, while its primary prescription program is advancing into a significant phase III clinical trial for major depressive disorder in adults.
Surgery is one of the most vulnerable experiences that a person can ever go through. They find it scary that in the 21st century, they still rely on paper instructions and human memory to get patients through this complicated journey. They can and they must do better. At SeamlessMD, they are on a mission to give every patient the best health outcomes after surgery. Together with healthcare providers, they leverage design, data and technology to enhance the patient experience, improve outcomes and lower costs.
Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through the advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, specializes in developing a healthcare platform and application aimed at Alzheimer’s patients. The company's flagship product, the Altoida iPad-based application, is the first validated solution on the market designed to predict the risk of Alzheimer’s Disease before symptoms appear, functioning as a computational biomarker. The application employs the Neuro Motor Index (NMI), which measures subtle micro-errors and micro-movements during everyday tasks, allowing for early detection of cognitive decline up to six years prior to the onset of typical neurodegenerative symptoms. The NMI test is intended for use by healthcare professionals as an adjunctive tool and is not a stand-alone diagnostic method. Altoida's medical device is classified as an FDA Class II medical device and CE marked as Class I, enabling early screening for Mild Cognitive Impairment (MCI) and monitoring cognitive function. After a brief testing period, healthcare providers receive real-time access to comprehensive patient reports via a secure, HIPAA-compliant web dashboard, making cognitive health assessments more affordable and accessible.
Winterlight Labs Inc. develops a speech-based platform for detecting cognitive and mental diseases such as, dementia and Alzheimer’s disease. Its AI (artificial intelligence) diagnostic platform assesses and monitors cognitive health by quantifying speech and language patterns. The company's platform has applications in clinical trials, long-term and primary care, and speech-language pathology. Winterlight Labs Inc. was founded in 2015 and is based in Toronto, Canada.
Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.
Nebula Genomics, founded in 2016 by Harvard genomics pioneer George Church and researchers Dennis Grishin and Kamal Obbad, operates an online marketplace for genomic and health data based in San Francisco, California. The company aims to facilitate genomic sequencing and health data sharing by allowing consumers to maintain control over their personal information and receive compensation for its use. By utilizing blockchain technology, Nebula Genomics eliminates intermediaries, enabling direct access to a rich repository of genetic data. This aggregated information serves researchers and the medical community, enhancing drug development and clinical trials while promoting personalized medicine. The company is supported by investors such as Khosla Ventures and Arch Venture Partners, and it also has a presence in Boston, Massachusetts.
Click Therapeutics, Inc. specializes in the engineering, validation, development, and commercialization of digital therapeutic solutions aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company offers innovative digital therapeutics for a range of conditions, including smoking cessation, major depressive disorder, schizophrenia, insomnia, and chronic pain. Its Digital Therapeutics™ are designed to function independently or alongside traditional biomedical treatments, utilizing the Clickometrics® adaptive data science platform to personalize user experiences and enhance engagement. Notably, Click's smoking cessation program has gained widespread access through various payers and providers, while its primary prescription program is advancing into a significant phase III clinical trial for major depressive disorder in adults.
Propeller Health is a mobile platform that offers sensors, mobile apps, analytics, and services to support respiratory health management. The HIPAA compliant platform stores users’ data in a cloud computing infrastructure. The Propeller sensor and mobile application help users learn more about and better manage their asthma, COPD, and respiratory disease. The Propeller sensor attaches to users’ inhalers and wirelessly syncs with their smartphones. It tracks their triggers and symptoms and sends personalized feedback and education to their phones based on the symptoms. Users can see how often they use the medication, and set up medication reminders and alerts. Propeller community enables users to share their Propeller data with their physician and family members. Propeller Health is backed by Safeguard Scientifics, The Social+Capital Partnership, California HealthCare Foundation, and other investors. The platform works with organizations such as Dignity Health, Wyckoff Heights Medical Center, Amerigroup Florida, and the City of Louisville. The system has been featured in The Economist, Washington Post, Fast Company, Wired, and Scientific American. Propeller Health has received TEDMED Innovation Showcase, White House Champion of Change, and Bluetooth Breakthrough Product awards. Propeller Health was launched by David Van Sickle, Greg Tracy, and Mark Gehring and its operations are based in Wisconsin, United States.
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors designed to analyze body fluids for health monitoring. Founded in 2012 and originally known as Electrozyme LLC, Biolinq aims to enhance the experience of individuals with diabetes by providing a more affordable and pain-free alternative to conventional continuous glucose monitoring (CGM) systems. The company's platform features minimally invasive electrochemical biosensors capable of measuring multiple analytes, including glucose, ketones, and lactate. This innovative technology not only facilitates easier blood glucose monitoring but also delivers actionable insights into metabolic health, significantly improving the quality of life for patients managing diabetes.
Prognos is a healthcare AI company dedicated to improving disease management through early intervention in collaboration with payers, life sciences, and diagnostics companies. It operates the Prognos Registry, which is the largest repository of clinical diagnostics information, encompassing over 5 billion medical records across more than 30 disease areas and covering 100 million patients. The company has developed 500 proprietary clinical algorithms that facilitate the early identification of patients, thereby enhancing treatment decision-making and risk management. Its platform, prognosFACTOR, efficiently analyzes vast amounts of lab and health records from over 325 million de-identified patients, providing rapid answers to clinically-focused healthcare inquiries. Prognos offers HIPAA-compliant healthcare data through its Prognos Marketplace, catering to various applications such as cohort design and health outcomes analysis, with a client base that includes a significant number of leading pharmaceutical manufacturers and payers.
Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through the advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.
Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.
Propeller Health is a mobile platform that offers sensors, mobile apps, analytics, and services to support respiratory health management. The HIPAA compliant platform stores users’ data in a cloud computing infrastructure. The Propeller sensor and mobile application help users learn more about and better manage their asthma, COPD, and respiratory disease. The Propeller sensor attaches to users’ inhalers and wirelessly syncs with their smartphones. It tracks their triggers and symptoms and sends personalized feedback and education to their phones based on the symptoms. Users can see how often they use the medication, and set up medication reminders and alerts. Propeller community enables users to share their Propeller data with their physician and family members. Propeller Health is backed by Safeguard Scientifics, The Social+Capital Partnership, California HealthCare Foundation, and other investors. The platform works with organizations such as Dignity Health, Wyckoff Heights Medical Center, Amerigroup Florida, and the City of Louisville. The system has been featured in The Economist, Washington Post, Fast Company, Wired, and Scientific American. Propeller Health has received TEDMED Innovation Showcase, White House Champion of Change, and Bluetooth Breakthrough Product awards. Propeller Health was launched by David Van Sickle, Greg Tracy, and Mark Gehring and its operations are based in Wisconsin, United States.
Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.